AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On August10, 2017, AveXis,Inc. (the “Registrant”) issued a press release announcing the Registrant’s financial results for the second quarter ended June30, 2017. A copy of this press release is furnished herewith as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.

The information in this Item 2.02 of this Current Report on Form8-K (including Exhibit99.1) is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

Exhibit Number

ExhibitDescription

99.1

Press Release, dated August10, 2017, titled “AveXis Reports Second Quarter 2017 Financial and Operating Results.”


AveXis, Inc. Exhibit
EX-99.1 2 a17-20022_1ex99d1.htm EX-99.1 Exhibit 99.1     Media Inquiries: Lauren Barbiero W2O Group 646-564-2156 [email protected]   Investor Inquiries: Jim Goff AveXis,…
To view the full exhibit click here

About AVEXIS,INC. (NASDAQ:AVXS)

AveXis, Inc., formerly Biolife Cell Bank, Inc., is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either carry a mutation in their SMN1 gene or their SMN1 genes have been deleted. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels. It also focuses to develop AVXS-101 to treat additional SMA types and other treatments for rare neurological genetic diseases.